BAY-3547926

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameBAY-3547926
Drug Alias Name225Ac-labelled GPC3 radioconjugate225Ac GPC3BAY3547926BAY-3547926
ClassificationBiologics > Protein drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[4] 
Mechanisms of ActionGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer AGBayer Healthcare Company Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A